{
  "id": "3dabce6b-6a20-4e75-816a-acf418af809f",
  "title": "Novo Nordisk seeks to block compounded Victoza",
  "link": "https://seekingalpha.com/news/4392489-novo-nordisk-seeks-to-block-compounded-victoza?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Fri, 03 Jan 2025 18:54:07 -0500",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "nvo",
    "teva",
    "lly"
  ],
  "byline": "Val Brickates Kennedy",
  "length": 338,
  "excerpt": "Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. Read more here.",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Healthcare, hapabapa/iStock Editorial via Getty ImagesNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded. In a Citizen Petition posted on Regulations.gov, Novo Nordisk (NVO) notedRecommended For YouMore Trending NewsSee More »",
  "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-test-id=\"grid-col-main\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003cdiv data-test-id=\"quick-links\"\u003e\u003cul\u003e\u003cli\u003e\u003ca data-test-id=\"theme-links-item\" href=\"https://seekingalpha.com/market-news/healthcare#source=section%3Amain_content%7Csection_asset%3Athemes%7Cbutton%3Ahealthcare%7Cfirst_level_url%3Anews\"\u003e\u003cspan\u003e\u003cspan\u003eHealthcare\u003c/span\u003e\u003c/span\u003e\u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-page-meta\"\u003e\u003cp\u003e\u003cspan data-test-id=\"post-primary-tickers\"\u003e, \u003c/span\u003e\u003c/p\u003e\u003c/div\u003e\u003c/header\u003e\u003cdiv\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cfigure data-type=\"getty-image\"\u003e\u003cpicture\u003e\u003cimg src=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750\" alt=\"New Nordisk\" data-id=\"1219304819\" data-type=\"getty-image\" width=\"4999px\" height=\"3331px\" srcset=\"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536 1536w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1280 1280w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1080 1080w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w750 750w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w640 640w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w480 480w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w320 320w, https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w240 240w\" sizes=\"(max-width: 768px) calc(100vw - 36px), (max-width: 1024px) calc(100vw - 132px), (max-width: 1200px) calc(66.6vw - 72px), 600px\"/\u003e\u003c/picture\u003e\u003cfigcaption data-type=\"getty-image\"\u003e\u003cp\u003ehapabapa/iStock Editorial via Getty Images\u003c/p\u003e\u003c/figcaption\u003e\u003c/figure\u003e\u003cp dir=\"ltr\"\u003eNovo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of drugs that are allowed to be compounded.\u003c/p\u003e \u003cp dir=\"ltr\"\u003eIn a Citizen Petition posted on Regulations.gov, Novo Nordisk (\u003ca href=\"https://seekingalpha.com/symbol/NVO\" title=\"Novo Nordisk A/S\"\u003eNVO\u003c/a\u003e) noted\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv data-test-id=\"recommended-section\"\u003e\u003cdiv\u003e\u003cp\u003e\u003ch4 data-test-id=\"recommended-for-you-card-title\"\u003eRecommended For You\u003c/h4\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003csection data-test-id=\"trending-card-container\"\u003e\u003cdiv\u003e\u003cdiv\u003e\u003cp\u003e\u003ch2 data-test-id=\"trending-card-title\"\u003eMore \u003cspan id=\"trending-news\"\u003eTrending News\u003c/span\u003e\u003c/h2\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv data-test-id=\"post-skeleton\"\u003e\u003c/div\u003e\u003c/div\u003e\u003cdiv\u003e\u003cp\u003e\u003ca id=\"cardFooterSeeMore\" data-test-id=\"card-footer-link\" aria-labelledby=\"trending-news cardFooterSeeMore\" href=\"https://seekingalpha.com/market-news#source=first_level_url%3Anews%7Csection%3Amain_content%7Csection_asset%3Amore_trending_news%7Cbutton%3Amore\"\u003e\u003cspan\u003eSee More »\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003c/div\u003e\u003c/section\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "Less than 1 min",
  "publishedTime": "2025-01-03T23:54:07Z",
  "modifiedTime": null
}
